This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mitchell, L. B. Search for Related Content PubMed PubMed Citation Articles by Mitchell, L. B.

Are lipid-lowering drugs also antiarrhythmic drugs?

an analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial

L. Brent Mitchell, MD, FACC^*,*, Judy L. Powell, BSN, Anne M. Gillis, MD, FACC^*, Victoria Kehl, PhC, Alfred P. Hallstrom, PhD the AVID Investigators

^* Foothills Hospital/University of Calgary, Calgary, Alberta, Canada
AVID Clinical Trial Center/University of Washington, Seattle, Washington, USA
Institut fuer Medizinische Statistik, Munich, Germany

View larger version (13K): [in a new window]   Figure 1 Kaplan-Meier survival curves for the outcome of freedom from ventricular tachyarrhythmia recurrence in patients with an implantable cardioverter defibrillator as a function of whether lipid-lowering drug therapy was not used (dashed line, no LL Rx) or was used early and consistently (solid line, LL Rx). VT/VF = ventricular tachycardia/ventricular fibrillation.

View larger version (12K): [in a new window]   Figure 2 Kaplan-Meier survival curves for the outcome of freedom from all-cause mortality as a function of whether lipid-lowering drug therapy was not used (dashed line, no LL Rx) or was used early and consistently (solid line, LL Rx).

View larger version (13K): [in a new window]   Figure 3 Kaplan-Meier survival curves for the outcome of freedom from cardiac mortality as a function of whether lipid-lowering drug therapy was not used (dashed line, no LL Rx) or was used early and consistently (solid line, LL Rx).